NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.

21. HOW does Normax plan to compete in the global mRNA-based pharma business?

Simple answer:

  • Nature is fundmentally not patentable. Nature is not a “monopoly business”
  • DNA translated into mRNA and expressed as Proteins, in the cell, is the basis for all life on earth.
  • Of about 10,000 diseases in humans, only 500 are currently treatable.
  • mRNA technology-based products can be safe and effective for many diseases and conditions.
  • Normax is an mRNA Freedom To Operate (FTO) business.
  • Generally, big-pharma are in the “monopoly” business, but in practice, no single company can monopolize the basic mRNA  business.
  • Normax plans to compete – on price – with safe and effective regulatory approved products, for a relatively unlimited global healthcare market demand/need.
  • The “IP landscape” must to be managed for FTO of the business – and it is this strategic FTO capability that is expected to be a competitive advantage for Normax.
By |2022-12-19T08:58:43+00:00December 18, 2022||Comments Off on 21. HOW does Normax plan to compete in the global mRNA-based pharma business?
Go to Top